• Explore /
  • Poster
  • / An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.

An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.

Abstract Poster

Authors

Tanios Bekaii-Saab

Tanios S. Bekaii-Saab

Mayo Clinic, Scottsdale, AZ

Tanios S. Bekaii-Saab , Mark Yarchoan , Muneeb Ahmed , David Michael Cohan , Wen Wee Ma

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05733598

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4178)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4178

Abstract #

TPS4178

Poster Bd #

495b

Abstract Disclosures

Similar Posters

First Author: Tanios S. Bekaii-Saab

First Author: Kevin Kim

First Author: Daneng Li

First Author: Dale Randall Shepard